Arrowhead Pharmaceuticals Inc

21 de ago. de 2026, 19:46 UTC

Arrowhead Pharmaceuticals shares are lower as Director Michael Perry sold 11,600 shares, reducing his ownership. Rising Treasury yields may also affect sentiment in biotechnology.

20 de ago. de 2026, 21:26 UTC

Arrowhead Pharmaceuticals Inc shares are lower during after-market hours. Broader market pressure from rising U.S. Treasury yields may be influencing sentiment.

19 de ago. de 2026, 19:26 UTC

Arrowhead Pharmaceuticals shares are higher Wednesday, supported by gains in the biotech sector, as the stock remains above its 20-day moving average.

18 de ago. de 2026, 23:01 UTC

Arrowhead Pharmaceuticals shares are lower in after-market hours, continuing a decline since Tuesday's close amid broader market concerns over rising U.S. Treasury yields.

14 de ago. de 2026, 19:26 UTC

Arrowhead Pharmaceuticals Inc shares are higher during Friday's session, trading above their 20-day moving average and near the top of their one-month range.

13 de ago. de 2026, 20:06 UTC

Arrowhead Pharmaceuticals Inc is declining today amid broader sector pressures, reflecting challenges in the biotech sector linked to the performance of LABU.

12 de ago. de 2026, 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

11 de ago. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

6 de ago. de 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.

5 de ago. de 2026, 21:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in after-market hours, reflecting strong performance and positioning above its 20-day moving average.

4 de ago. de 2026, 23:02 UTC

Arrowhead Pharmaceuticals shares fell in after-market trading following a net loss of $194.280 million and an EPS of -$1.36 in its fiscal Q3 results.

3 de ago. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in Monday's session. Broader market positivity follows President Trump's military announcement, impacting crude oil prices.

31 de jul. de 2026, 19:16 UTC

Arrowhead Pharmaceuticals shares are lower, reflecting broader pressures in the biotechnology sector amid rising inflation concerns linked to increased crude oil prices.

30 de jul. de 2026, 23:06 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, with no specific news identified to explain the movement amid broader market volatility.

29 de jul. de 2026, 20:09 UTC

RBC Capital raised Arrowhead Pharmaceuticals' price target to $100 from $87, contributing to positive sentiment and modest gains since Tuesday's close.

28 de jul. de 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and significant declines in other indices.

27 de jul. de 2026, 19:02 UTC

Arrowhead Pharmaceuticals completed enrollment in its Phase 3 YOSEMITE trial for zodasiran, with H.C. Wainwright and Morgan Stanley raising price targets to $115 and $120, respectively.

24 de jul. de 2026, 19:12 UTC

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $120, but shares are trading lower amid increased market volume during Friday's session.

23 de jul. de 2026, 10:16 UTC

Arrowhead Pharmaceuticals shares rise in pre-market trading, building on Wednesday's gains after positive drug trial results and a price target increase to $115 from $90.

22 de jul. de 2026, 22:06 UTC

Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies, boosting shares higher in after-market trading.

21 de jul. de 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc. shares declined in after-market trading, remaining below the 20-day moving average and near the lower end of the one-month range.

20 de jul. de 2026, 20:21 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours, declining from a high to a low amid unusual trading activity and no specific news identified.